3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
Bevacizumab
21
Paclitaxel
19
Carboplatin
15
pembrolizumab
14
Specimen Handling
14
liposomal doxorubicin
12
Magnetic Resonance Spectroscopy
12
Cyclophosphamide
11
olaparib
10
Gemcitabine
10
fludarabine
9
Topotecan
8
Biopsy
8
Fulvestrant
7
niraparib
6
Nivolumab
6
palbociclib
5
Taxes
5
Immunoglobulin G
5
Doxorubicin
5
Disulfides
5
aldesleukin
4
trastuzumab deruxtecan
3
mirvetuximab soravtansine
3
binimetinib
3
Oxaliplatin
3
Cisplatin
3
AZD5305
3
1-dodecylpyridoxal
3
ulixertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Blood Component Removal
×
30 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled